Nu-Med Plus (NUMD) Net Income towards Common Stockholders (2012 - 2025)
Nu-Med Plus (NUMD) posted Net Income towards Common Stockholders of -$12618.0 for Q4 2025, down 5.45% sequentially from -$11966.0 in Q3 2025, and down 19.55% YoY from -$15683.3 in Q4 2024.
Nu-Med Plus (NUMD) Net Income towards Common Stockholders (2012 - 2025) Analysis & Trends
Nu-Med Plus has reported Net Income towards Common Stockholders for 14 years, with the latest figure at -$12618.0 in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 19.55% year-over-year to -$12618.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$56182.0 (up 17.8% YoY) and the FY2025 annual result came in at -$56182.0, up 17.8% from the prior year.
- Net Income towards Common Stockholders retreated to -$12618.0 in Q4 2025 per NUMD's latest filing, from -$11966.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $42606.0 in Q4 2022 and troughed at -$2.2 million in Q4 2021.
- A 5-year average of -$164315.7 and a median of -$23073.0 in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2021 and 2022: Net Income towards Common Stockholders plunged 330.45% in 2021, then soared 101.95% in 2022.
- Over 5 years, Net Income towards Common Stockholders stood at -$2.2 million in 2021, then jumped by 101.95% to $42606.0 in 2022, then sank by 232.84% to -$56596.0 in 2023, then surged by 81.35% to -$10555.0 in 2024, then decreased by 19.55% to -$12618.0 in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$12618.0, -$11966.0, and -$11665.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.67 Bn | 194.07 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 129.56 Bn | 126.09 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 119.87 Bn | 110.65 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.80 Bn | 73.27 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 52.66 Bn | 48.41 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.56 Bn | 32.61 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 34.16 Bn | 32.05 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.44 Bn | 23.12 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Nu-Med Plus | 1.82 Mn | 1.82 Mn | - | 19,670.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12,618.00 |
| Sep 30, 2025 | -11,966.00 |
| Jun 30, 2025 | -11,665.00 |
| Mar 31, 2025 | -19,933.00 |
| Dec 31, 2024 | -10,555.00 |
| Sep 30, 2024 | -18,677.00 |
| Jun 30, 2024 | -17,287.00 |
| Mar 31, 2024 | -21,826.00 |
| Dec 31, 2023 | -56,596.00 |
| Sep 30, 2023 | -16,406.00 |
| Jun 30, 2023 | -24,320.00 |
| Mar 31, 2023 | -28,204.00 |
| Dec 31, 2022 | 42,606.00 |
| Sep 30, 2022 | -58,050.00 |
| Jun 30, 2022 | -58,070.00 |
| Mar 31, 2022 | -59,653.00 |
| Dec 31, 2021 | -2.19 Mn |
| Sep 30, 2021 | -118,366.00 |
| Jun 30, 2021 | -242,606.00 |
| Mar 31, 2021 | -356,748.00 |